Daily text reminders to support pelvic floor exercises after prostate surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Men undergoing radical prostatectomy for prostate cancer or laser enucleation for benign prostatic hyperplasia at the University of Rochester will be enrolled and divided into two cohorts by procedure. Each cohort is split into an intervention arm that receives daily automated SMS reminders to perform pelvic floor exercises plus standard care and a control arm that receives standard care only. Urinary incontinence will be measured with the patient-reported Michigan Incontinence Symptom Index (M-ISI) and collected via SMS questionnaires. Outcomes will compare M-ISI scores between the reminder and control groups to see if reminders improve continence recovery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Planning to undergo a radical prostatectomy (RALP) or laser enucleation of the prostate (LEP) procedure
2. Patient of URMC Urology
3. Adult male 18 years of age and older
4. Able to read, write, and speak in English (NOTE: due to limitations with questionnaire validation, only English-speaking subjects are permitted)
5. Has access to a mobile device capable of receiving automated text messages.
6. Willing to receive text messages and to complete questionnaires via SMS text.
7. Willingness to participate and able to provide informed consent.

Exclusion Criteria:

1. Less than 18 years of age
2. Unable to send and receive SMS texts
3. Unable to read, write, and speak English
4. Catheter dependency
5. Has or plans to have Artificial Urinary Sphincter or Urethral Sling during the study period
6. In the opinion of the investigator, the subject has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate.

Where it's running

• 158 Sawgrass clinic; Suite 3100
  Rochester, New York, United States Recruiting

Study contacts

• Study coordinator: Austin Jackson
• Email: Austin_jackson@urmc.rochester.edu
• Phone: (585) 275-0126

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.